Role of rs7903146 polymorphism and adropin serum level in patients with diabetes mellitus; a case–control study from Isfahan, Iran

Palizban, Abbasali; Yazdani, Abdol-Hamid; Jahanbani-Ardakani, Hamidreza

doi:10.1080/13813455.2019.1684951

Cited by 8 publications

(11 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It should be noted that studies assessing diabetes and adropin concentrations have some contradictory findings. While the majority of studies have reported decreased adropin with diabetes, adropin has also been reported to be increased with type I diabetes in rats (18), T2D (161,162), and gestational diabetes (163).…”

Section: Circulating Adropinmentioning

confidence: 98%

Role of adropin in arterial stiffening associated with obesity and type 2 diabetes

Jurrissen

Ramirez‐Perez

Cabral-Amador

et al. 2022

American Journal of Physiology-Heart and Circulatory Physiology

View full text Add to dashboard Cite

Adropin is a peptide largely secreted by the liver and known to regulate energy homeostasis; however, it also exerts cardiovascular effects. Herein, we tested the hypothesis that low circulating levels of adropin in obesity and type 2 diabetes (T2D) contribute to arterial stiffening. In support of this hypothesis, we report that obesity and T2D is associated with reduced levels of adropin (in liver and plasma) and increased arterial stiffness in mice and humans. Establishing causation, we show that mesenteric arteries from adropin knockout mice are also stiffer, relative to arteries from wild-type counterparts, thus recapitulating the stiffening phenotype observed in T2D db/db mice. Given the above, we performed a set of follow-up experiments, in which we found that: 1) exposure of endothelial cells or isolated mesenteric arteries from db/db mice to adropin reduces filamentous actin (F-actin) stress fibers and stiffness; 2) adropin-induced reduction of F-actin and stiffness in endothelial cells and db/db mesenteric arteries is abrogated by inhibition of nitric oxide (NO) synthase; and 3) stimulation of smooth muscle cells or db/db mesenteric arteries with a NO mimetic reduces stiffness. Last, we demonstrated that in vivo treatment of db/db mice with adropin for four weeks reduces stiffness in mesenteric arteries. Collectively, these findings indicate that adropin can regulate arterial stiffness, likely via endothelial-derived NO, and thus support the notion that "hypoadropinemia" should be considered as a putative target for the prevention and treatment of arterial stiffening in obesity and T2D.

show abstract

Section: Circulating Adropinmentioning

confidence: 98%

Role of adropin in arterial stiffening associated with obesity and type 2 diabetes

Jurrissen

Ramirez‐Perez

Cabral-Amador

et al. 2022

American Journal of Physiology-Heart and Circulatory Physiology

View full text Add to dashboard Cite

show abstract

Section: Study Characteristicsmentioning

confidence: 99%

“…Table 1 summarizes the characteristics of the 15 eligible studies [24,27,[91][92][93][94][95][96][97][98][99][100][101][102][103]. These studies were published between 2014 and 2022, and conducted in China (n = 7) [24,91,93,94,98,101,103], Iran (n = 3) [27,92,100], Turkey (n = 2) [95,99], Iraq (n = 1) [96], India (n = 1) [102], and Ukraine (n = 1) [97]. Of all included studies, four studies were performed using a case-control design [27,92,95,96], and eleven had a cross-sectional design [24,91,93,94,[97][98][99][100][101][102][103].…”

Section: Study Characteristicsmentioning

confidence: 99%

“…These studies were published between 2014 and 2022, and conducted in China (n = 7) [24,91,93,94,98,101,103], Iran (n = 3) [27,92,100], Turkey (n = 2) [95,99], Iraq (n = 1) [96], India (n = 1) [102], and Ukraine (n = 1) [97]. Of all included studies, four studies were performed using a case-control design [27,92,95,96], and eleven had a cross-sectional design [24,91,93,94,[97][98][99][100][101][102][103]. Thirteen studies enrolled both male and female participants [24,[91][92][93][94][95][97][98][99][100][101][102][103]; while two studies exclusively included females [96] or males [27].…”

Section: Study Characteristicsmentioning

confidence: 99%

See 1 more Smart Citation

Circulating levels of adropin and diabetes: a systematic review and meta-analysis of observational studies

et al. 2023

View full text Add to dashboard Cite

Objective Adropin, a newly identified regulatory protein has garnered attention given its potential role in metabolism regulation, especially glucose metabolism and insulin resistance. However, studies on the association between adropin and type 2 diabetes mellitus (T2DM) are equivocal. The aim of this study is to assess the association between serum adropin levels and T2DM using a systematic review and meta-analysis of observational studies. Methods PubMed, Scopus, ISI Web of science, and Google Scholar were searched, up to August 2022, for studies that reported the association between serum levels of adropin in adults with T2DM compared to a control group without diabetes. A random-effect model was used to compute the pooled weighted mean difference (WMD) with 95% confidence intervals (CI). Results Meta-analysis of 15 studies (n = 2813 participants) revealed that the serum adropin concentrations were significantly lower in patients with T2DM compared with the control group (WMD= -0.60 ng/mL, 95% CI: -0.70 to -0.49; I2 = 99.5%). Subgroup analysis also found lower concentration of adropin in patients with T2DM who were otherwise healthy compared to a control group (n = 9; WMD=-0.04 ng/ml, 95% CI= -0.06 to -0.01, p = 0.002; I2 = 96.4). Conclusions Our study showed adropin levels are lower in patients with diabetes compared to a control group without diabetes. However, the limitations of observational studies challenge the validity of the results, and further investigations are needed to confirm the veracity of these findings and additionally explore possible mechanisms.

show abstract

“…TT genotype carriers had the highest adropin serum level whereas healthy people with CC genotype had the lowest adropin serum level. The rs7903146T/T and rs7903146C/T genotypes also increased the risk of T2DM [ 314 ].…”

Section: Introductionmentioning

confidence: 99%

Single-nucleotide polymorphisms as important risk factors of diabetes among Middle East population

et al. 2022

View full text Add to dashboard Cite

Diabetes is a chronic metabolic disorder that leads to the dysfunction of various tissues and organs, including eyes, kidneys, and cardiovascular system. According to the World Health Organization, diabetes prevalence is 8.8% globally among whom about 90% of cases are type 2 diabetes. There are not any significant clinical manifestations in the primary stages of diabetes. Therefore, screening can be an efficient way to reduce the diabetic complications. Over the recent decades, the prevalence of diabetes has increased alarmingly among the Middle East population, which has imposed exorbitant costs on the health care system in this region. Given that the genetic changes are among the important risk factors associated with predisposing people to diabetes, we examined the role of single-nucleotide polymorphisms (SNPs) in the pathogenesis of diabetes among Middle East population. In the present review, we assessed the molecular pathology of diabetes in the Middle East population that paves the way for introducing an efficient SNP-based diagnostic panel for diabetes screening among the Middle East population. Since, the Middle East has a population of 370 million people; the current review can be a reliable model for the introduction of SNP-based diagnostic panels in other populations and countries around the world.

show abstract

Role of rs7903146 polymorphism and adropin serum level in patients with diabetes mellitus; a case–control study from Isfahan, Iran

Cited by 8 publications

References 25 publications

Role of adropin in arterial stiffening associated with obesity and type 2 diabetes

Role of adropin in arterial stiffening associated with obesity and type 2 diabetes

Circulating levels of adropin and diabetes: a systematic review and meta-analysis of observational studies

Single-nucleotide polymorphisms as important risk factors of diabetes among Middle East population

Contact Info

Product

Resources

About